Cognition Therapeutics Inc Total Liabilities
Cognition Therapeutics Inc total liabilities. Based on the latest financial reports, Cognition Therapeutics Inc (CGTX) has total liabilities worth $6.87 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Cognition Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Cognition Therapeutics Inc (2019–2024)
Total liabilities of Cognition Therapeutics Inc from 2019 to 2024. This chart illustrates how Cognition Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Cognition Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Cognition Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kyungdong Gas
KO:012320
|
Korea | ₩115.39 Billion |
|
Kredyt Inkaso SA
WAR:KRI
|
Poland | zł564.43 Million |
|
Croda International PLC
LSE:CRDA
|
UK | GBX1.23 Billion |
|
Scully Royalty Ltd
NYSE:SRL
|
USA | $124.67 Million |
|
Gamma Nu Inc
KQ:192410
|
Korea | ₩61.48 Billion |
|
360 Capital REIT
AU:TOT
|
Australia | AU$88.18 Million |
|
Thantawan Industry Public Company Limited
BK:THIP
|
Thailand | ฿1.55 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Cognition Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cognition Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Cognition Therapeutics Inc Total Liabilities Ratios Explained
Cognition Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cognition Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cognition Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Cognition Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.48 Million | +7.44% |
| 2023-12-31 | $10.69 Million | +5.04% |
| 2022-12-31 | $10.18 Million | +29.40% |
| 2021-12-31 | $7.86 Million | -89.56% |
| 2020-12-31 | $75.30 Million | +14.30% |
| 2019-12-31 | $65.88 Million | -- |
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2… Read more